Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 7, 2006 - Issue 14
Submit an article Journal homepage
55
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Recent evidence of sustained benefit with exenatide in Type 2 diabetes

RATNER RE, MAGGS D, NIELSEN LL et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. (2006) 8:419-428 and BLONDE L, KLEIN EJ, HAN J et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. (2006) 8:436-447.

Sheila A Doggrell Senior Lecturer in Pharmacology, School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia. [email protected]
Pages 2003-2006 | Published online: 04 Oct 2006

Bibliography

  • KORO CE, BOWLIN SJ, BOURGEOIS N, FEDDER DO: Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care (2004) 27:17-20.
  • INZUCCHI SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002) 287:360-372.
  • BOJANOWSKA E: Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med. Sci. Monit. (2005):RA271-RA278.
  • ZANDER M, MADSBAD S, MADSEN JL, HOLST JJ: Effect of 6-week course of glucagon-like peptide1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 359:824-830.
  • GOKE R, FEHMANN HC, LINN T et al.: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. (1993) 268:19650-19655.
  • DEFRONZO RA, RATNER RE, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 28:1092-1100.
  • RATNER RE, MAGGS D, NIELSEN LL et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. (2006) 8:419-428.
  • PURNELL JQ, WEYER C: Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol. (2003) 2:33-47.
  • BUSE JB, HENRY RR, HAN J et al.: Effect of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 27:2628-2635.
  • KENDALL DM, RIDDLE MC, ROSENSTOCK J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 28:1083-1091.
  • BLONDE L, KLEIN EJ, HAN J et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. (2006) 8:436-447.
  • RIDDLE MC, HENRY RR, POON TH et al.: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. (2006) [Epub ahead of print].
  • DOGGRELL SA: Is exenatide advancing the treatment of type 2 diabetes. Expert Opin. Pharmacother. (2006) 7:109-112.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.